1. Home
  2. Directory
  3. Wisconsin
  4. Wauwatosa
  5. Pathology
  6. NPI Profile
  7. Prescriptions 1033282967

DR. JOSE G. ARAUJO MD
Prescription History 1033282967
Pathology - Anatomic Pathology & Clinical Pathology in Wauwatosa, WI

NPI Status: Active since November 16, 2006

Contact Information

11803 W NORTH AVE
WAUWATOSA, WI
ZIP 53226
Phone: (414) 258-5522
Fax: (414) 258-1337

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JOSE G. ARAUJO MD, an active Anatomic Pathology & Clinical Pathology specialist practicing in Wauwatosa, WI. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 372 documented patient claims. Among these therapy options, the most frequently utilized medication is Buprenorphine-Naloxone, which accounts for 159 claims alone.

Medication Index

Buprenorphine-Naloxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Pathology
Provider Metrics Summary
Total Claims 159
30-Day Fills 159.5
Days Supply 4,590
WI State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills60.4
Peer Average Days Supply1,168
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 165.0% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $42,371.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$266.49

State Avg Cost Per Claim

$184.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Dextroamphetamine-Amphetamine

Generic Formulation: Dextroamphetamine/AmphetamineSpecialty: Pathology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 561
WI State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills36.7
Peer Average Days Supply1,073
Conservative Utilization

This provider writes prescriptions for this formulation 45.7% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $846.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.57

State Avg Cost Per Claim

$39.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills. This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.

Gabapentin

Generic Formulation: GabapentinSpecialty: Pathology
Provider Metrics Summary
Total Claims 52
30-Day Fills 52.0
Days Supply 1,560
WI State Average Benchmarks
Peer Average Claims84.0
Peer Average 30-Day Fills138.8
Peer Average Days Supply4,044
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $963.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.53

State Avg Cost Per Claim

$24.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Methylphenidate Hcl

Generic Formulation: Methylphenidate HclSpecialty: Pathology
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 780
WI State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.1
Peer Average Days Supply726
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,248.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$46.24

State Avg Cost Per Claim

$38.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Methylphenidate belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills.

Suboxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Pathology
Provider Metrics Summary
Total Claims 86
30-Day Fills 86.0
Days Supply 2,464
WI State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.3
Peer Average Days Supply651
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 168.8% higher than the standard regional baseline profile for WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $66,061.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$768.16

State Avg Cost Per Claim

$430.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Ubrelvy

Generic Formulation: UbrogepantSpecialty: Pathology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 313
WI State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills31.6
Peer Average Days Supply747
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.3% less volume than the regional standard for practitioners inside WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,587.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,053.42

State Avg Cost Per Claim

$1,173.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat migraine. Ubrogepant may work by changing the amount of a certain natural substance in the brain. It helps to relieve headache, pain, and other migraine symptoms (including nausea, vomiting, sensitivity to light/sound). Prompt treatment helps you return to your normal routine and may decrease your need for other pain medications. This medication is not used to prevent future migraines or lessen how often you get migraines.

Zubsolv

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Pathology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 520
WI State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.9
Peer Average Days Supply385
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,903.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$939.06

State Avg Cost Per Claim

$490.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JOSE G. ARAUJO MD provides transparency into local medical care patterns within Wauwatosa, WI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Anatomic Pathology & Clinical Pathology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.